Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.

NCT07599800 is registered in ClinicalTrials.gov with Andros Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07599800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07599800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.
Lead sponsor
Andros Pharmaceuticals Co., Ltd.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 31, 2029
Enrollment
333 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

phn - post-herpetic neuritis